Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of Selgantolimod-containing combination therapies for chronic hepatitis B has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Selgantolimod (Selgantolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis B | Phase 2 | Status: COMPLETED | Results posted: 2025-07-24